Skip to main
NTRA

Natera (NTRA) Stock Forecast & Price Target

Natera (NTRA) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 33%
Buy 60%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Natera Inc. is projected to experience significant revenue growth primarily driven by its Signatera molecular residual disease testing, which has shown a remarkable 54% year-over-year increase in volumes. The company has reported an impressive revenue beat of approximately $80 million in the third quarter and has revised its 2025 revenue guidance upwards by $160 million, reflecting strong operational performance. Furthermore, Natera's initiatives to expand reimbursement coverage in additional cancer types are expected to enhance average selling prices and improve gross margins, thereby bolstering operating cash flow.

Bears say

Natera Inc faces a negative outlook primarily due to eroding margins caused by reductions in in-network pricing and the potential inclusion of average risk patients, which could further compress average selling prices for its Panorama product. Regulatory setbacks or unfavorable reimbursement scenarios may delay the company's expansion efforts and adversely impact product adoption, leading to heightened risks for its financial performance. Consequently, without strong data or successful navigation of these challenges, Natera's future growth potential appears limited, which could negatively affect its market position and investor sentiment.

Natera (NTRA) has been analyzed by 15 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 60% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Natera (NTRA) Forecast

Analysts have given Natera (NTRA) a Buy based on their latest research and market trends.

According to 15 analysts, Natera (NTRA) has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $238.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $238.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Natera (NTRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.